Putative substrates for cyclic nucleotideâ€dependent p airway smooth muscle tone

Autonomic and Autacoid Pharmacology

11, 365-398

DOI: 10.1111/j.1474-8673.1991.tb00260.x

Citation Report

#	Article	IF	Citations
1	POSTER COMMUNICATIONS. British Journal of Pharmacology, 1992, 107, 108P.	2.7	7
2	Î²-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sciences, 1993, 52, 2101-2109.	2.0	59
3	Leukotriene D₄ receptors are not negatively coupled to adenylyl cyclase in guineaâ€pig lung parenchyma. British Journal of Pharmacology, 1993, 108, 824-832.	2.7	8
4	Comparison of the effects of selective inhibitors of phosphodiesterase types III and IV in airway smooth muscle with differing Î²â€adrenoceptor subtypes. British Journal of Pharmacology, 1993, 108, 57-61.	2.7	51
5	Effects of rolipram and siguazodan on the human isolated bronchus and their interaction with isoprenaline and sodium nitroprusside. British Journal of Pharmacology, 1993, 109, 774-778.	2.7	43
7	Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents. Annual Reports in Medicinal Chemistry, 1994, , 185-194.	0.5	16
8	Phosphoinositide metabolism in airway smooth muscle. , 1994, 62, 221-245.		17
9	Î²-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends in Pharmacological Sciences, 1994, 15, 370-374.	4.0	120
10	Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle. British Journal of Pharmacology, 1995, 116, 2510-2516.	2.7	17
11	Comparative effects of activation of soluble and particulate guanylyl cyclase on cyclic GMP elevation and relaxation of bovine tracheal smooth muscle. British Journal of Pharmacology, 1995, 115, 723-732.	2.7	18
12	The effect of isoenzymeâ€selective PDE inhibitors on methacholineâ€induced contraction of guineaâ€pig and rat ileum. British Journal of Pharmacology, 1996, 118, 2131-2139.	2.7	15
13	Salbutamol potentiates the relaxant effects of selective phosphodiesterase inhibitors on guinea pig isolated trachea. Fundamental and Clinical Pharmacology, 1996, 10, 356-367.	1.0	9
14	Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo. European Journal of Pharmacology, 1997, 327, 57-63.	1.7	6
15	Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. European Journal of Pharmacology, 1997, 332, 97-107.	1.7	18
16	Effects of salbutamol on intracellular calcium oscillations in porcine airway smooth muscle. Journal of Applied Physiology, 1997, 82, 1836-1843.	1.2	25
17	PHOSPHODIESTERASE IV INHIBITORS SYNERGISTICALLY POTENTIATE RELAXATION INDUCED BY FORSKOLIN IN GUINEA-PIG TRACHEA. Clinical and Experimental Pharmacology and Physiology, 1998, 25, 114-119.	0.9	10
18	Modulation of spasmogen-stimulated Ins(1,4,5)P3 generation and functional responses by selective inhibitors of types 3 and 4 phosphodiesterase in airways smooth muscle. British Journal of Pharmacology, 1998, 124, 47-54.	2.7	12
19	Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. British Journal of Pharmacology, 1998, 124, 229-237.	2.7	84

#	Article	IF	Citations
20	Phosphodiesterase Isozymes. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 351-370.	2.5	642
21	Bronchoprotective Effect of an Intrabronchial Administration of Cilostazol Powder and a Nebulized PDE1 and PDE4 Inhibitor KF19514 in Guinea Pigs. International Archives of Allergy and Immunology, 1998, 116, 220-227.	0.9	3
22	Food Restrictionâ€“Mediated Adrenal Influences on Antigenâ€“Induced Bronchoconstriction and Airway Eosinophil Influx in the Guinea Pig. International Archives of Allergy and Immunology, 1998, 117, 52-59.	0.9	18
23	Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis. British Journal of Pharmacology, 1999, 128, 327-336.	2.7	17
24	Extracellular signal-regulated kinase 1/2 control Ca2+ -independent force development in histamine-stimulated bovine tracheal smooth muscle. British Journal of Pharmacology, 2000, 131, 981-989.	2.7	7
25	Cyclic AMP elevating agents and nitric oxide modulate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. British Journal of Pharmacology, 2001, 133, 485-494.	2.7	10
26	Evidence that the anti-spasmogenic effect of the Î² -adrenoceptor agonist, isoprenaline, on guinea-pig trachealis is not mediated by cyclic AMP-dependent protein kinase. British Journal of Pharmacology, 2001, 133, 1201-1212.	2.7	40
27	Pentoxifylline induces the shedding of L-selectin on polymorphonuclear cells by stimulation via adenosine receptor as well as by the inhibition of phosphodiesterase. Modern Rheumatology, 2001, 11, 65-71.	0.9	1
28	Adenosine 3â€²,5â€²-Cyclic Monophosphate (cAMP)-Dependent Inhibition of IL-5 from Human T Lymphocytes Is Not Mediated by the cAMP-Dependent Protein Kinase A. Journal of Immunology, 2001, 167, 2074-2080.	0.4	70
29	Role of protein kinase A in the inhibition of human mast cell histamine release by Î²-adrenergic receptor agonists. Allergology International, 2002, 51, 197-203.	1.4	4
30	Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. British Journal of Pharmacology, 2002, 135, 1872-1881.	2.7	42
31	Apoptosis and Nitrative Stress Associated with Phosphodiesterase Inhibitor-Induced Mesenteric Vasculitis in Rats. Toxicologic Pathology, 2003, 31, 638-645.	0.9	34
32	Chapter 4 Membrane and cellular signaling of integrity and acute activation. Advances in Molecular and Cell Biology, 2005, 35, 105-138.	0.1	1
33	NO responsiveness in pulmonary artery and airway smooth muscle: the role of cGMP regulation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L200-L208.	1.3	8
34	Î² 2 -Adrenergic Receptor Genotype and Pulmonary Function in Patients With Heart Failure. Chest, 2006, 130, 1527-1534.	0.4	24
35	Bronchodilator Effect of Infused B-Type Natriuretic Peptide in Asthma. Chest, 2006, 130, 66-72.	0.4	21
36	Influence of Î² 2 -Adrenergic Receptor Genotype on Airway Function During Exercise in Healthy Adults. Chest, 2006, 129, 762-770.	0.4	45
38	ENDOGENOUS NITRIC OXIDE ATTENUATES ?-ADRENOCEPTOR-MEDIATED RELAXATION IN RAT AORTA. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 95-101.	0.9	13

#	Article	IF	Citations
39	Beta-Adrenergic Agonists. Pharmaceuticals, 2010, 3, 1016-1044.	1.7	62
40	Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews, 2012, 64, 450-504.	7.1	379
41	Impact of chronic systolic heart failure on lung structure-function relationships in large airways. Physiological Reports, 2016, 4, e12867.	0.7	10
42	GS-5759, a Bifunctional Î²₂-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 324-340.	1.3	14
43	Molecular dynamic simulations reveal suboptimal binding of salbutamol in T164I variant of Î²2 adrenergic receptor. PLoS ONE, 2017, 12, e0186666.	1.1	34
44	The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respiratory Research, 2017, 18, 146.	1.4	19
45	Bronchodilator Therapy for Asthma. , 2018, , 1-31.		0
46	Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects ofÎ²₂-Adrenoceptor Agonists. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 220-236.	1.3	13
47	Bronchodilator Therapy for Asthma. , 2019, , 841-871.		0
48	Membrane-facilitated receptor access and binding mechanisms of long-acting Î²2-adrenergic receptor (Î²2-AR) agonists. Molecular Pharmacology, 2021, 100, MOLPHARM-AR-2021-000285.	1.0	5
49	Bronchodilators: Basic Pharmacology. , 1995, , 391-417.		9
50	Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: Biochemistry, pharmacology and therapeutic potential in asthma. , 1993, 40, 9-32.		38
51	Control of Tracheobronchial Microvascular Permeability. , 1994, , 307-373.		1
52	Purines. , 1995, , 271-307.		3
53	Cyclic AMP and the Control of Airways Smooth Muscle Tone. , 1994, , 215-232.		7
54	Cyclic Nucleotide Phosphodiesterases in Airways Smooth Muscle. , 1994, , 271-308.		1
55	Modulation of Agonist-Stimulated Phosphoinositide Turnover in Airways Smooth Muscle by Cyclic Nucleotide-Dependent and Independent Mechanisms. , 1994, , 309-327.		3
56	Muscarinic receptor-Î²-adrenoceptor cross-talk in airways smooth muscle. , 2001, , 121-157.		3

#	Article	IF	Citations
57	Tracheal preparations. , 1998, , 71-90.		1
58	Biochemical Characteristics and Cellular Regulation of Phosphodiesterase IV. , 1993, 43, 51-71.		25
61	Adrenaline and Noradrenaline. , 1995, , 1-79.		0
62	Airways Smooth Muscle: Neurotransmitters, Amines, Lipid Mediators and Signal Transduction. , 1995, , .		4
63	Neural Control of Airway Function in Asthma. , 1998, , 389-407.		0
64	Î²-Adrenoceptors. , 1999, , 101-124.		0